8 December 2017Americas

Non-profit group continues battle against Gilead patents

Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Americas

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Americas

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Americas

PTAB rejects IPR challenges to Gilead patents

14 June 2018 The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

Americas

PTAB shoots down tenth I-MAK Gilead challenge

24 July 2018 The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.